Curb J D, Hardy R J, Labarthe D R, Borhani N O, Taylor J O
Hypertension. 1982 Mar-Apr;4(2):307-11. doi: 10.1161/01.hyp.4.2.307.
Recent reports on the efficacy of pharmacological management in reducing mortality associated with mild hypertension have enhanced the importance of increasing our knowledge about drug toxicity. The Hypertension Detection and Follow-Up Program (HDFP) provides a convenient setting in which to examine the association reported between reserpine usage and breast cancer. In the intensively treated and followed group (Stepped Care [SC]), the relative breast cancer experience of those who did take reserpine and those who did not was examined. Of 2529 females in SC, 1036 received reserpine, with an average exposure of 1.97 years during 5 years of follow-up. Through extensive investigation, 21 cases of breast cancer were identified. using a life table regression method of analysis to adjust for actual time of reserpine exposure, race, sex, and medication status at entry, and comparing those who took reserpine with those who did not, the author's calculated a risk ratio of 1.28, with a confidence interval of 0.58 to 2.80. Adjustment for a number of other variables known to have relationships to breast cancer did not appreciably change the results. Thus, with certain precautions, the authors conclude that in this setting there is no indication of the recently postulated association of reserpine and the short-term enhancement of breast tumor growth.
近期有关药物治疗在降低轻度高血压相关死亡率方面疗效的报告，凸显了增加我们对药物毒性了解的重要性。高血压检测与随访项目（HDFP）为研究利血平使用与乳腺癌之间报告的关联提供了便利条件。在强化治疗和随访组（阶梯式护理[SC]）中，对服用利血平和未服用利血平的人群的乳腺癌发病情况进行了研究。在SC组的2529名女性中，1036人服用了利血平，在5年随访期间平均暴露时间为1.97年。通过广泛调查，确定了21例乳腺癌病例。作者采用生命表回归分析方法，对利血平实际暴露时间、种族、性别以及入组时的用药状况进行调整，并将服用利血平的人与未服用利血平的人进行比较，计算出风险比为1.28，置信区间为0.58至2.80。对其他一些已知与乳腺癌有关的变量进行调整后，结果没有明显变化。因此，作者得出结论，在采取某些预防措施的情况下，在这种情况下没有迹象表明利血平与近期推测的乳腺癌肿瘤生长短期增强之间存在关联。
